Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Comment by Smokey1958on Mar 11, 2021 8:54am
107 Views
Post# 32770902

RE:RE:NEWS

RE:RE:NEWS

Can't disagree with you, Boubouna ....so yes maybe a little desperation but calculated as well. Speculative valuation, maintaining momentum and having an appropriate sp to move away from are all important. This is also a very different set of circumstances that the management has never had to deal with ....so some growing pains for sure.

By releasing this carefully worded NR they, maybe (as you opine, in desperation) they make up for this miscalculation of February. Good strategy or bad? If it has the potential to allay any fears of both longterm investors and those waiting on the sidelines ....and these are now the most critical steps.

They went a long time without an NR, people complained .....they put more of them out ....some others will complain. Regardless of how one "feels" these are the most critical steps of this process and as shareholders get closer to the day of reckoning most would rather have some insight as to how these steps are proceeding .....regardless of the material affect on the sp.

Cheers! Always enjoy your insight ....food for thought.

GLTY and GLTA!!!


boubouna wrote: Honestly and in all sincerity...I don't see why this is news?  They already mentioned in the last NR that this would happen...all they have done now is tell us that the clinical trial hasn't even started yet and only an application has been submitted? In my opinion, they were desperate to put something out and it makes me question their strategy? 

We are waiting for the reults of this trial...that's the 'meat' we are looking for!!  This anticipation of 'news' all the time combined with so-so 'news' being released is becoming a tad exhausting....hope the market reacts at least...

 

<< Previous
Bullboard Posts
Next >>